Eklira Genuair aclidinium bromide regulatory update

Kyorin said Japan approved Eklira Genuair aclidinium bromide for relief from symptoms arising from respiratory tract obstruction in patients with chronic obstructive pulmonary disorder (COPD). The product is an inhalable long-acting, selective M2 and M3 muscarinic receptor antagonist delivered using the Genuair inhaler. The product is approved as Tudorza Pressair in the U.S. and as Bretaris/Eklira Genuair in the EU. ...